Zydus Cadila Q4 net up 73% to Rs 679 cr, total income up a marginal 3%

During Q4FY21, firm launched Virafin to treat moderate infections in adult Covid-19 patients. Its ZyCoV-D plasmid DNA vaccine is at an advanced stage of Phase-3 trials

Zydus Cadila posted a 73 per cent surge in its net profit, year on year, to Rs 679 crore for the quarter ended March 31, 2021.
 
However, the company's total income from operations grew by just three per cent to Rs 3,847 crore, from Rs 3,752 crore during corresponding period of the previous year.
 
For the full year ended March 31, 2021, the company had a consolidated net profit of Rs 2,134 crore and total income from operations of Rs 15,102 crore.
 
Zydus Cadila's domestic business grew 18 per cent during the quarter to Rs 1,772 crore,